Abbreviated Prescribing Information
TEZSPIRE PEN (Tezepelumab)

Presentation: Tezepelumab 210 mg in 1.91 mL (110 mg/mL) solution for injectionin pre-filled pen. Indications: Asthma: Add-on maintenance treatment in adults andadolescents 12 years and older with severe asthma who are inadequately controlleddespite high dose inhaled corticosteroids plus another medicinal product formaintenance treatment. Chronic rhinosinusitis with nasal polyps (CRSwNP): Add- ontherapy with intranasal corticosteroids for the treatment of adult patients withsevere CRSwNP for whom therapy with systemic corticosteroids, and/or surgery donot provide adequate disease control. Dosage: Asthma and CRSwNP:Subcutaneous injection every 4 weeks. Contraindications: Hypersensitivity to theactive substance or to any of the excipients (Glacial acetic acid, L-proline,Polysorbate 80, Sodium hydroxide, Water for injection.) Precautions: Should not beused to treat acute asthma exacerbations; Seek medical advice if asthma remainsuncontrolled or worsens after initiation of treatment; Abrupt discontinuation ofcorticosteroids after initiation of Tezepelumab is not recommended. Reduction incorticosteroid doses should be gradual and performed under the supervision of aphysician; Patients with pre-existing serious infections or helminth infections shouldbe treated before initiating therapy with Tezepelumab; In the event of a serioushypersensitivity reaction (e.g. anaphylaxis), administration of Tezepelumab shouldbe discontinued immediately and appropriate treatment as clinically indicatedshould be initiated; If patients develop a serious cardiac event while receivingTezepelumab treatment, therapy with Tezepelumab should be discontinued untilthe acute event stabilises. Interactions: No formal drug interaction studies havebeen conducted. The use of live attenuated vaccines should be avoided in patientsreceiving Tezepelumab. Undesirable Effects: Arthralgia, pharyngitis,hypersensitivity (including anaphylactic reaction), rash and injection site reactions.Full local prescribing information is available upon request. API.HK.TEZ.1125 ​

HK-13332 27/8/2026